Bryan Roberts, Venrock

Board Member

Bryan joined Venrock in 1997. He is based in Palo Alto and seeks to partner with early-stage entrepreneurs innovating across the healthcare and life sciences industries. Bryan is currently involved with several companies across therapeutics, genomics, and health tech, including Aledade, Devoted Health, Element Biosciences, Encoded Therapeutics, Included Health (formerly portfolio companies Grand Rounds & Doctor on Demand), Kelonia Therapeutics, Lyra Health, SmithRx, and Suki.ai. Past investments include 10x Genomics (NASDAQ: TXG), Ariosa Diagnostics (acquired by Roche), athenahealth (NASDAQ: ATHN), Fate Therapeutics (NASDAQ: FATE), Ikaria (acquired by Mallinckrodt), Illumina (NASDAQ: ILMN), Ironwood Pharmaceuticals (NASDAQ: IRWD), Receptos (acquired by Celgene), Sirna Therapeutics (acquired by Merck), and Zeltiq (acquired by Allergan).  

Immediately prior to joining Venrock, Bryan received his PhD in chemistry & chemical biology from Harvard University. He received his BA from Dartmouth College.